Journal article
Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program
SM Garland, AM Cornall, JML Brotherton, JD Wark, MJ Malloy, SN Tabrizi
Vaccine | ELSEVIER SCI LTD | Published : 2018
Abstract
Objectives: The VACCINE [Vaccine Against Cervical Cancer Impact and Effectiveness] study evaluated the prevalence of quadrivalent vaccine-targeted human papillomavirus (HPV) genotypes (HPV 6, 11, 16, 18) amongst young women of vaccine-eligible age. Methods: Between October 2011 – June 2015, women aged 18–25 years from Victoria, Australia, were recruited through targeted advertising on the social networking website Facebook. Participants completed an online questionnaire and provided a self-collected vaginal swab for HPV DNA detection and genotyping (Linear Array HPV genotyping assay). Self-reported HPV vaccination details were verified with the National HPV Vaccination Program Register (NHVP..
View full abstractGrants
Funding Acknowledgements
We gratefully acknowledge the Victorian Cancer Agency as our funding body. We thank Elisa Young, Sarah Osborne, Margaret Nugyen, Iris Tung, Fiona Tan and David Hawkes for project management and co-ordination at various periods of the study and Adele Rivers for participant recruitment and management. We also acknowledge Houda Abdo, Angela Hurley, Marin Poljak and Sam Phillips for completing all HPV genotyping analyses and Athena Costa for assisting with the manuscript submission. We thank the NHVPR staff who assisted with the study. The NHVPR is owned by the Australian Government Department of Health and operated by VCS Limited. We especially thank all of the participants who volunteered for the Vaccine study.